摘要:
A process for the preparation of a 15 .alpha.-hydroxyprostaglandin intermediate of the formula ##STR1## wherein R.sub.1 is phenoxymethyl, phenoxymethyl substituted on the phenyl moiety by halogen or trifluoromethyl, or alkyl of 1-5 carbon atoms, andR.sub.2 is hydrogen, acetyl, benzoyl or p-phenylbenzoyl,which comprises stereospecifically microbiologically reducing a corresponding 15-ketone of the formula ##STR2## with a strain of the microorganism Kloeckera, Saccharomyces or Hansenula.
摘要:
5-Cyanoprostacyclins of Formula I ##STR1## wherein A is a --CH.sub.2 --CH.sub.2 --, trans--CH.dbd.CH--, or --C.tbd.C-group,W is a free or functionally modified hydroxymethylene group or a free or functionally modified ##STR2## wherein the OH-group can be in the .alpha.- or .beta.-position, D and E together form a direct bond orD is the group ##STR3## a straight-chain, saturated alkylene group of 1-5 carbon atoms, a branched, saturated or a straight-chain, unsaturated alkylene group of 2-5 carbon atoms, any of which can optionally be substituted by fluorine atoms,n is the number 1, 2, or 3,E is oxygen, sulfur, a --C.tbd.C-bond, a direct bond, or a --CR.sub.4 .dbd.CR.sub.5 -group wherein R.sub.4 and R.sub.5 are different and can be a hydrogen atom or an alkyl group of 1-3 carbon atoms,R.sub.2 is an alkyl, cycloalkyl, optionally substituted aryl, or heterocyclic group,R.sub.1 is a free or functionally modified hydroxy group, andR.sub.3 is an acetal residue ##STR4## wherein R.sub.6, R.sub.7, R.sub.8, R.sub.9, R.sub.10 and R.sub.11 can be identical or different and each is a hydrogen atom or a straight-chain or branched alkyl group of 1-5 carbon atoms, or a substituted or unsubstituted phenyl residue,have valuable pharmacological properties.
摘要:
A microbiological process for sterospecific monoketo reduction of racemic 3-keto-bicyclic carbacyclin intermediates to the corresponding optically active 30.alpha. hydroxy compounds is provided.
摘要:
Process for the production of optically active (+)-bicyclo[3.3.0]octanol derivatives of formula (+)-I, in which R.sub.1 and R.sub.2 represent jointly an oxygen atom or the double-bond residue --O--X--O-- with X as a straight or branched-chain alkylene with 1-7 C-atoms, or R.sub.1 and R.sub.2 represent separately the residue OR.sub.5 with R.sub.5 as a straight or branched-chain alkyl with 1-7 C-atoms, and R.sub.3 the residue COOZ with Z as a hydrogen atom, straight or branched chain alkyl with 1-7 C atoms, cycloalkyl with 3-6 C atoms, phenyl or aralkyl with 7-10 atoms or R.sub.3 is the residue --(CH.sub.2).sub.n --O--COR.sub.4 with n having the meaning 1-4 and R.sub.4 as a straight or branched-chain alkyl with 1-7 C atoms, cycloalkyl with 3-6 C atoms, phenyl or aralkyl with 7-10 C atoms. The process is characterized in that racemic 3.alpha.-cyloxy-cis-bicyclo[3.3.0]-octane derivatives of formula (+)-II, wherein R.sub.1, R.sub.2 R.sub.3 and R.sub.4 have the above meanings, are subjected enzymatically or microbiologically to a stereospecific acylate hydrolsis and the (+)-bicyclo[3.3.0]-octanol derivative produced is separated from the unsaponified bicyclo[3.3.0]-octanol acylate of formula (-)-II or the unsaponified enantiomers (+)-II are separated from the saponified bicyclo[3.3.0]octanol derivative (-)-I and then subjected to chemical acylate hydrolysis.
摘要:
The invention relates to a process for manufacturing optically active carbacyclin intermediate products from racemic cis-bicyclo[3.3.0]octane-2-carboxylic acids. This process makes it possible in an advantageous way to produce important intermediates for the synthesis of stable and pharmacologically active carbacyclin derivatives.
摘要:
Bicycloalkanes of the formula ##STR1## WHEREIN N IS THE INTEGER 1 OR 2; R is methyl or ethyl, and X and Y collectively are a free or ketalized oxo group or X is a hydrogen atom and y is a free, etherified or esterified hydroxy group, are produced by hydrogenating a compound of the formula ##STR2## WHEREIN N, R, X, and Y have the values given above and Me is an alkali metal atom, in an aqueous solution with hydrogen and a palladium-, platinum- or rhodium-containing hydrogenation catalyst. The corresponding free acid is obtained by acidifying the reaction mixture and isolating the reaction product.
摘要:
A process for production of 15-alpha-hydroxyprostaglandin intermediates of formula I ##STR1## wherein X is CH.sub.2,A is trans --CH.dbd.CH--B is ethylenedioxy or 2,2-dimethylpropylenedioxy,R.sub.1 is benzoyl, andR.sub.2 is ##STR2## by treating a ketone of formula II ##STR3## wherein A, B, X, R.sub.1 and R.sub.2 have the meanings indicated above, with a culture of Candida solani (NCYC 41) and isolating the resulting 15-alpha-hydroxyprostaglandin intermediate.
摘要:
Steroids of the formula ##STR1## wherein represents a single or double bond,X is hydrogen, fluorine or methyl;Y is hydrogen, hydroxy or alkanoyloxy of 1-6 carbon atoms;Z is hydrogen or methyl;V is methylene, ethylidene, hydroxymethylene or vinylidene; andR.sub.1 is alkyl of 1-6 carbon atoms or alkyl of 2-6 carbon atoms with an oxygen atom between two of the carbon atoms;R.sub.2 is hydrogen or alkyl of 1-6 carbon atoms, orR.sub.1 and R.sub.2 together form a tri- or tetramethylene group provided that Y is hydroxy or alkanoyloxy;have pharmacological activity and are useful as intermediates for preparing other pharmacologically active steroids.
摘要:
Corticoids of the formula ##STR1## wherein represents a single bond or a double bond;X is hydrogen, fluorine, chlorine or methyl;Y is hydrogen and Z is hydrogen, fluorine or chlorine, orY and Z together are a carbon-to-carbon bond;V is .beta.-hydroxymethylene, .beta.-chloromethylene or carbonyl;W is methylene, ethylidene or vinylidene;Q is oxygen or sulfur;R.sub.1 is alkyl of 1-8 carbon atoms, alkyl of 2-8 carbon atoms with an oxygen atom between two of the carbon atoms or benzyl, and R.sub.2 is hydrogen or alkyl of 1-4 carbon atoms, orR.sub.1 and R.sub.2 collectively are trimethylene or tetramethylene; andR.sub.3 is hydrogen, fluorine, chlorine, hydroxy, or hydroxy esterified by a C.sub.1-16 hydrocarbon carboxylic acid have valuable pharmacological properties, e.g., anti-inflammatory activity.